Silexion Therapeutics Corp (SLXN)

Jan 29, 2025, 5:30 PM EST - 24 days ago

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Jan 29, 2025, 9:59 AM EST - 24 days ago

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Jan 28, 2025, 8:29 AM EST - 25 days ago

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Jan 16, 2025, 12:08 PM EST - 5 weeks ago

Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies

Jan 16, 2025, 11:04 AM EST - 5 weeks ago

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Jan 16, 2025, 8:51 AM EST - 5 weeks ago

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

LUV

Jan 15, 2025, 8:00 PM EST - 5 weeks ago

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Jan 15, 2025, 4:01 PM EST - 5 weeks ago

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Jan 13, 2025, 7:50 AM EST - 5 weeks ago

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Dec 17, 2024, 9:36 AM EST - 2 months ago

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

AMGN

Nov 22, 2024, 4:30 PM EST - 3 months ago

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Nov 20, 2024, 8:30 AM EST - 3 months ago

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Oct 1, 2024, 6:45 AM EDT - 5 months ago

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Sep 24, 2024, 9:25 AM EDT - 5 months ago

Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise

Sep 24, 2024, 7:30 AM EDT - 5 months ago

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

Sep 9, 2024, 7:32 AM EDT - 5 months ago

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Sep 3, 2024, 4:05 PM EDT - 6 months ago

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

Aug 15, 2024, 4:05 PM EDT - 6 months ago

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination